Corcept Therapeutics Incorporated. (CORT)

Corcept Therapeutics' stock price has experienced significant volatility over the past six months. The share price declined by 31.99% between March 27, 2025, and March 26, 2026. The FDA issued a Complete Response Letter for relacorilant, and Corcept faced a patent challenge defeat. The company missed revenue and GAAP EPS estimates in Q4 CY2025. Corcept's stock surged following the FDA approval of Lifyorli™, and an insider purchase was made. A securities fraud class action lawsuit was announced against Corcept Therapeutics.

The demand seasonality for Corcept Therapeutics products shows a poor consistency score. March has historically been the strongest month, while July tends to be the weakest month. The stock has an average annual return of 32.43%.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company focused on discovering and developing medications that modulate cortisol effects to treat severe disorders. Their primary product is Korlym, used for controlling hyperglycemia in adult patients with endogenous Cushing's syndrome. The company also has a pipeline of selective cortisol modulators, including Relacorilant, Miricorilant, Dazucorilant, and Nenocorilant.

Corcept Therapeutics is headquartered in Redwood City, California, and primarily operates in the United States. The company focuses on medication discovery and development within the U.S. and markets Korlym there, with potential future expansion into global markets.

Corcept Therapeutics' brand reputation has been influenced by regulatory and legal events. The FDA's Complete Response Letter for relacorilant negatively impacted the company's reputation, as did the patent litigation. Missing analyst expectations for revenue and EPS in Q4 CY2025 also affected the reputation. The FDA approval of Lifyorli™ provided a boost to the company's reputation. The securities fraud lawsuit could impact the company's reputation for transparency and investor trust.

Corcept Therapeutics has a mixed ownership structure including institutional, insider, and retail investors. Institutional investors hold a significant portion of the stock. Insiders also own a substantial percentage of the company. Public companies and individual investors hold the remaining portion of the stock.